Advertisement
Advertisement
ALZN
Alzamend Neuro, Inc. Common Stock
1.41
USDSponsored
-0.14
-9.03%
Nov 06, 15:58 UTC -5
Closed
Pre-Market
1.48
+0.07
+4.61%
Alzamend Neuro, Inc. Common Stock (ALZN) Earnings
ALZN Earnings Reports
Positive Surprise Ratio
ALZN beat 10 of 19 last estimates.
53%
Next Report
Date of Next Report
Dec 07, 2026
Estimate for Q2 27 (Revenue/ EPS)
--
/-$0.23
Implied change from Q1 27 (Revenue/ EPS)
--
/-66.18%
Implied change from Q2 26 (Revenue/ EPS)
--
/-23.33%
Alzamend Neuro, Inc. Common Stock earnings per share and revenue
On Sep 10, 2026, ALZN reported earnings of -0.68 USD per share (EPS) for Q1 27, missing the estimate of -0.57 USD, resulting in a -19.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.18% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 4 analysts forecast an EPS of -0.23 USD, with revenue projected to reach -- USD, implying an decrease of -66.18% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Aligos Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$2.21
Actual
-$2.09
Surprise
+5.58%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
Creative Medical Technology Holdings, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.40
Surprise
-63.40%
Medicus Pharma Ltd. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$6.75
Actual
-$11.64
Surprise
-72.25%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Bio-Techne Corp.
Report Date
Nov 06, 2026 For Q1 27
Estimate
$0.44
Actual
$0.44
Surprise
-1.96%
Immunocore Holdings plc - ADR
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.28
Surprise
-104.08%
Entera Bio Ltd. Ordinary Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.11
Surprise
-58.50%
Vogenx Inc Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.47
Surprise
-187.99%
Agenus Inc.
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.02
Surprise
+107.26%
FAQ
What were Alzamend Neuro, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Alzamend Neuro, Inc. Common Stock reported EPS of -$0.68, missing estimates by -19.05%, and revenue of $0.00, 0% as expectations.
How did the market react to Alzamend Neuro, Inc. Common Stock's Q1 2027 earnings?
The stock price moved up 1.18%, changed from $1.70 before the earnings release to $1.72 the day after.
When is Alzamend Neuro, Inc. Common Stock expected to report next?
The next earning report is scheduled for Dec 07, 2026.
What are the forecasts for Alzamend Neuro, Inc. Common Stock's next earnings report?
Based on 4
analysts, Alzamend Neuro, Inc. Common Stock is expected to report EPS of -$0.23 and revenue of -- for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.